Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
S768I occurs in approximately 1-2% of EGFR mutated NSCLCs and has demonstrated transforming capacity in vitro.
“This point mutation occurs in approximately 1–2% of EGFR mutated NSCLCs, demonstrated transforming capacity in vitro”
S768I is associated with variable responses to EGFR TKIs but collectively seems less sensitive than common mutations to first-generation agents.
“it has been associated with variable responses to EGFR TKIs, but collectively seems less sensible than common mutations to first generation agents [82,83].”
The citation lists haven’t been fetched yet
References 6 · Cited by 7
- Authors
- Russo, A., Franchina, T., Ricciardi, G. R. R., & Adamo, V.
- Affiliations
- University of Messina (IT)
- Corresponding author
- Adamo, Vincenzo
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 12
- Issue
- 1
- Pages
- e6-e8
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2564183684
- Cited by
- 7
- References
- 6
- Citations by year
- 2023: 1 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- T790M mutation, afatinib, non-small cell lung cancer, lung adenocarcinoma, acquired resistance, EGFR tyrosine kinase inhibitors, first-line therapy, EGFR exon 20 mutations, uncommon EGFR mutations, treatment response, lobectomy, cardiovascular comorbidity, tyrosine kinase inhibitor toxicity
- MeSH terms
- Afatinib, Carcinoma, Non-Small-Cell Lung, Exons, Humans, Lung Neoplasms, Mutation, Quinazolines, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
